PipelineReview.com - All Products

Show Cart

All Products

Results 101 - 120 of 207

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

Sep 2016 Competitor Analysis Immunotoxins 2016

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

(Discount: 33.33%)

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Jun 2016 Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

(Discount: 50.00%)

Jun 2016 Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Mar 2016 Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins

Feb 2016 Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

Feb 2016 Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

Shopping cart

Cart empty

Latest report

PSMA-Targeted Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

Shopping cart

Cart empty

Latest report

PSMA-Targeted Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing